SciTegic Licenses Pipeline Pilot to Euroscreen
SciTegic® announced the licensing of their lead technology, Pipeline PilotTM, to Euroscreen s.a. for three years. Euroscreen will implement Pipeline Pilot as an important element of their technology platform enabling new capacities for their cheminformatics and data management efforts. The Pipeline Pilot software system employs novel approaches to processing drug discovery data through flexible automated pipelines for faster data processing and analysis. With this collaborative licensing agreement, Pipeline Pilot can be used by Euroscreen scientists to accelerate their drug discovery research.
“After reviewing many options available to us, we have selected Pipeline Pilot to become one of the key elements of our process for chemo-informatics and HTS data analysis,” said Frédéric Ooms, Chemistry Project Manager for Euroscreen.
“Using the wide, integrative capability and the speed of Pipeline Pilot, our data processing capabilities will be improve considerably, allowing us to make better decisions faster, we intend to use Pipeline Pilot as an ETL tool to help the creation of our corporate data warehouse.” said François Roman, Vice President R&D for Euroscreen.
“Euroscreen has built an impressive technology platform for identifying new drugs interacting with GPCRs, and their inclusion of Pipeline Pilot is a great endorsement,” said Dr. Mathew Hahn, CEO of SciTegic. “We look forward to working with Euroscreen to explore some of the innovative new areas in which they may be able to employ Pipeline Pilot.”
About SciTegic
SciTegic, Inc. is a privately held San Diego company that develops and markets informatics software to the pharmaceutical and biotechnology industries. The company is pioneering a new technology approach called “Data Pipelining” to process drug discovery data with unprecedented flexibility. This new methodology has established its utility by accelerating informatics research for nearly 1000 users at over one 100 customer sites worldwide.
About Euroscreen
Euroscreen is a world leader in G-protein coupled receptors (GPCRs). The Company integrates its research expertise in this area with its patented high-throughput AequoScreen™ cellular assay platform to patent new GPCR targets and drug candidates The Company is building its own patent portfolio of GPCR targets and novel drug leads for licensing to biopharmaceutical companies, and to date has agreements with Galapagos Genomics, ICOS, Merck & Co, Pfizer Inc, Solvay, Syngenta, UCB, CyBio AG and EvotecOAI. Euroscreen has also established collaborations with academic centres, such as Brussels University, Mount Sinai School of Medicine, the University of Georgia Research Foundation and the University of Toronto, for access to its GPCR-based products (recombinant cell lines and membrane preparations) and services (custom screening and research services). Euroscreen is a privately held company based in Brussels, Belgium. The Company was spun out of the University of Brussels in 1994 by Professors Jacques Dumont, Marc Parmentier and Gilbert Vassart and has since raised more than €8m in equity funding and grants. Euroscreen currently has 80 employees of which 50 are in R&D.
